<code id='89D15873B6'></code><style id='89D15873B6'></style>
    • <acronym id='89D15873B6'></acronym>
      <center id='89D15873B6'><center id='89D15873B6'><tfoot id='89D15873B6'></tfoot></center><abbr id='89D15873B6'><dir id='89D15873B6'><tfoot id='89D15873B6'></tfoot><noframes id='89D15873B6'>

    • <optgroup id='89D15873B6'><strike id='89D15873B6'><sup id='89D15873B6'></sup></strike><code id='89D15873B6'></code></optgroup>
        1. <b id='89D15873B6'><label id='89D15873B6'><select id='89D15873B6'><dt id='89D15873B6'><span id='89D15873B6'></span></dt></select></label></b><u id='89D15873B6'></u>
          <i id='89D15873B6'><strike id='89D15873B6'><tt id='89D15873B6'><pre id='89D15873B6'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:12684
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Gene therapies for deafness raise the question: Do deaf people want a 'cure'?
          Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

          Advancesingenetherapycouldeventually"cure"manyformsofcongenitaldeafness.Thechangeshavemanydeafpeople

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Stigma and the return of syphilis

          AtissuesampleshowingthepresenceofsyphilisSkipVanOrden/CDCviaAPSyphilis,oneoftheoldestinfectionsknown